Clinical trials in Galdakao – page 12

445 clinical trials in Galdakao, Spain across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in SpainEnsayosClinicos.es

Galdakao at a glance

445

clinical trials

Research sites1

Quick filters

445 trials in Galdakao

Open in trial search

Myotonic dystrophy

Recruiting

Long-Term Safety and Efficacy Study of Mexiletine Hydrochloride for Patients with Myotonic Dystrophy Type 1 and Type 2

InvestigationalNo placebo

Long-Term Safety and Efficacy Study of Mexiletine Hydrochloride for Patients with Myotonic Dystrophy Type 1 and Type 2

InvestigationalNo placebo

Spain

Participants:0–17 years · 18–64 years · 65+ years
Substances:Mexiletine Hydrochloride
Sponsor:Lupin Atlantis Holdings S.A.

Contact Research Centre

Prostate cancer

Recruiting

Comparison of Short vs Long-term Hormone Therapy with Goserelin, Leuprorelin, or Triptorelin Combined with Radiation for Prostate Cancer Patients After Surgery

Registered drugNo placebo

Comparison of Short vs Long-term Hormone Therapy with Goserelin, Leuprorelin, or Triptorelin Combined with Radiation for Prostate Cancer Patients After Surgery

Registered drugNo placebo

Spain

Participants:18–64 years
Substances:Bicalutamide
Sponsor:Instituto De Investigacion En Oncología Radioterapica FEOR

Contact Research Centre

Metastases to central nervous system+1

Recruiting

Study on the Safety and Effectiveness of Repotrectinib for Patients with ROS1-Positive Non-Small Cell Lung Cancer and Active Brain Metastasis

InvestigationalNo placebo

Study on the Safety and Effectiveness of Repotrectinib for Patients with ROS1-Positive Non-Small Cell Lung Cancer and Active Brain Metastasis

InvestigationalNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Repotrectinib
Sponsor:Medica Scientia Innovation Research S.L.

Contact Research Centre

Neuroblastoma+1

Recruiting

Study of ABTL0812, Irinotecan, and Temozolomide for Children with Relapsed or Refractory Neuroblastoma and Other Solid Tumors

Registered drugNo placebo

Study of ABTL0812, Irinotecan, and Temozolomide for Children with Relapsed or Refractory Neuroblastoma and Other Solid Tumors

Registered drugNo placebo

Spain

Participants:0–17 years · 18–64 years
Substances:Irinotecan
Sponsor:Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca

Contact Research Centre

Acute myeloid leukaemia

Recruiting

Study on Treating Acute Myeloid Leukemia in Children and Adolescents Using Daunorubicin, Mitoxantrone, and a Drug Combination

Registered drugNo placebo

Study on Treating Acute Myeloid Leukemia in Children and Adolescents Using Daunorubicin, Mitoxantrone, and a Drug Combination

Registered drugNo placebo

Spain

Participants:0–17 years · 18–64 years
Substances:Cytarabine
Sponsor:Vaestra Goetalandsregionen

Contact Research Centre

Squamous cell carcinoma of head and neck

Recruiting

Study on Pembrolizumab and Radiotherapy for Patients with Limited Spread of Head and Neck Cancer

Registered drugNo placebo

Study on Pembrolizumab and Radiotherapy for Patients with Limited Spread of Head and Neck Cancer

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:European Organisation For Research And Treatment Of Cancer

Contact Research Centre

Ependymoma

Recruiting

Study on Ependymoma Treatment in Children, Adolescents, and Young Adults Using Cisplatin, Cyclophosphamide, Etoposide, and a Drug Combination

Registered drugNo placebo

Study on Ependymoma Treatment in Children, Adolescents, and Young Adults Using Cisplatin, Cyclophosphamide, Etoposide, and a Drug Combination

Registered drugNo placebo

Spain

Participants:0–17 years · 18–64 years
Substances:Cisplatin
Sponsor:Centre Leon Berard

Contact Research Centre

Rhabdomyosarcoma

Recruiting

Study of drug combinations including irinotecan, ifosfamide, vincristine, dactinomycin, regorafenib and other agents for children and adults with rhabdomyosarcoma

Registered drugNo placebo

Study of drug combinations including irinotecan, ifosfamide, vincristine, dactinomycin, regorafenib and other agents for children and adults with rhabdomyosarcoma

Registered drugNo placebo

Spain

Participants:0–17 years · 18–64 years · 65+ years
Substances:Cyclophosphamide
Sponsor:The University Of Birmingham

Contact Research Centre

Sickle cell disease+1

Recruiting

Long-term safety study of oral etavopivat tablets in children, adolescents and adults with sickle cell disease or thalassaemia who completed previous etavopivat treatment

InvestigationalNo placebo

Long-term safety study of oral etavopivat tablets in children, adolescents and adults with sickle cell disease or thalassaemia who completed previous etavopivat treatment

InvestigationalNo placebo

Spain

Participants:0–17 years · 18–64 years · 65+ years
Substances:Etavopivat
Sponsor:Novo Nordisk A/S

Contact Research Centre

Cerebral haemorrhage

Recruiting

Study on the Effects of Continuing or Stopping Simvastatin and Atorvastatin in Patients with Spontaneous Lobar Intracerebral Hemorrhage

Registered drugNo placebo

Study on the Effects of Continuing or Stopping Simvastatin and Atorvastatin in Patients with Spontaneous Lobar Intracerebral Hemorrhage

Registered drugNo placebo

Spain

Participants:18–64 years
Substances:Atorvastatin
Sponsor:Fundacio Institut De Recerca De L Hospital De La Santa Creu I Sant Pau

Contact Research Centre

Neuroblastoma

Recruiting

Study on High-Risk Neuroblastoma Treatment with Busulfan, Melphalan, and Drug Combination for Patients with Insufficient Metastatic Response

Registered drugNo placebo

Study on High-Risk Neuroblastoma Treatment with Busulfan, Melphalan, and Drug Combination for Patients with Insufficient Metastatic Response

Registered drugNo placebo

Spain

Participants:0–17 years · 18–64 years
Substances:Busulfan
Sponsor:Institut Gustave Roussy

Contact Research Centre

Systemic scleroderma+1

Recruiting

Study on the Effects of Belimumab in Adults with Systemic Sclerosis-Associated Interstitial Lung Disease

Registered drug

Study on the Effects of Belimumab in Adults with Systemic Sclerosis-Associated Interstitial Lung Disease

Registered drug

Spain

Participants:18–64 years · 65+ years
Substances:Belimumab
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Other cities in Spain

The busiest research cities in the country

All 203 cities in Spain

Clinical research in Galdakao

What the registry says about research in the country

01 Oncology Research

Groundbreaking studies focusing on breast cancer treatments, including trials for HER2-positive and triple-negative variants. Research encompasses innovative therapies for pancreatic adenocarcinoma and colon cancer.

Advanced breast cancer therapies
Neoadjuvant chemotherapy approaches
Metastatic cancer treatments

Multiple trials evaluating novel drug combinations and targeted therapies for improved patient outcomes.

02 Pulmonary Medicine

Comprehensive research into pulmonary fibrosis and respiratory conditions, with studies examining new treatments for COPD and pulmonary embolism management.

Interstitial lung diseases
Progressive pulmonary conditions
Respiratory therapy optimization

Innovative approaches to improve lung function and patient quality of life.

03 Cardiovascular Studies

Investigations into cardiomyopathy prevention and treatment, including trials for acute coronary syndromes and peripheral arterial disease management.

Genetic cardiac conditions
Vascular disease treatments
Antiplatelet therapy optimization

Focus on preventive strategies and improved treatment protocols for heart conditions.

04 Additional Therapeutic Areas

Studies addressing endocrine disorders, including hypothyroidism and its effects. Research on hepatic conditions and smoking cessation therapies.

Liver disease management
Addiction treatment
Hormonal disorders

Diverse therapeutic approaches targeting various medical conditions.

Back to Spain All countries